{"filing":{"accession_number":"0001493152-26-042744","cik":"0001692415","ticker":"CODX","company_name":"Co-Diagnostics, Inc.","form":"8-K","filing_date":"2026-09-15","report_date":"2026-08-25","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1692415/000149315226042744/form8-k.htm"},"events":[{"id":33607,"run_id":30908,"accession_number":"0001493152-26-042744","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics in August 2026 to evaluate compatibility of ReadyGo's sample collection and preparation technologies with the Company's Co-Dx PCR platform. The filing emphasizes the agreement is \"material\" and describes it as a strategic evaluation of complementary technologies to enhance the Co-Dx platform's usability in decentralized testing environments. While preliminary and non-binding, this represents a material operational/strategic partnership evaluation that would inform investors about the Company's product development trajectory and potential technology integration opportunities.","company_name":"Co-Diagnostics, Inc.","ticker":"CODX","filing_date":"2026-09-15","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":37095,"accession_number":"0001493152-26-042744","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics in August 2026 to evaluate compatibility of ReadyGo's sample collection and preparation technologies with the Company's Co-Dx PCR platform. The filing emphasizes the agreement is \"material\" and describes it as a strategic evaluation of complementary technologies to enhance the Co-Dx platform's usability in decentralized testing environments. While preliminary and non-binding, this represents a material operational/strategic partnership evaluation that would inform investors about the Company's product development trajectory and potential technology integration opportunities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-15T20:08:39.576522+00:00","company_name":"Co-Diagnostics, Inc.","ticker":"CODX","filing_date":"2026-09-15"}]}